# Research Pulse — 2026-08-14 _Generated 2026-08-14 07:31 KST · AI × Bioresearch Daily synthesis_ Brown Biotech daily research pulse — multi-front synthesis across CRISPR / gene editing, AI drug discovery, protein AI, single-cell foundation models, FDA/regulatory, and spatial transcriptomics. Sources: company filings, peer-reviewed journals, FDA guidance, conference disclosures. --- ### Post 1: 오늘의 전체 흐름 🧬 **AI × Bioresearch Daily — 8월 14일 (금요일) · Accelerating(가속화 Day)** 8/14(가속화)→8/13(Catalyzing)→8/12(Consolidating)→8/11(Integrating)→8/10(Translating)→8/9(Converging)→8/8→8/7(Transcribing)→8/6(Industrializing)→8/5(Maturing)→8/4(Verifying)→8/3→...→7/14(가속). Catalyzing(8/13)된 기술들이 **다음 단계 산업화·임상 적용을 가속화(Accelerating)하는 날** — Kresladi LAD-I gene therapy FDA 승인(2026.3.26)으로 rare disease 치료 패러다임 관리→분자적 근절로 전환(Sheikh Annals Medicine 2026), DNA/RNA editing technologies가 in vivo applications 핵심 bottleneck( delivery efficiency·tissue specificity·genotoxicity·immunogenicity) 체계적 분석으로 치료 잠재력 확대 확인(Rui Zhao Molecular Biomedicine 2026), AlphaFold2/3 monomeric 88%/dimeric 77% accuracy + ESMFold monomeric 76%/dimeric 41%로 protein structure prediction benchmarking 체계 확립(Mahtha NAR Genomics Bioinformatics 2026), 1.1 million predicted protein complex structures atlas로 37,855 high-confidence human interactome 구조 Atlas 확장(Qi Nature Communications 2026), CAPTAIN이 RNA+protein 동시 예측으로 transcriptome-only foundation models의 근본적 한계 극복 + COVID-19 immune interaction patterns 관련 hypothesis 생성(Ji Nature Communications 2026), FDA gene therapy approvals가 38개 CGT 분석에서 expedited pathway 92.1%/surrogate endpoints 44.7% 의존으로 timely access 우선하나 limited premarket data 문제 확인(Oo J Clinical Pharmacology 2026 + Shahzad Clinical Pharmacology 2026)이 동시에 진행된다. Accelerating은 Catalyzing의 다음 단계다. 오늘 6개 전선은 촉매화된 기술들이 산업화·임상 적용 속도를 높이는 가속화 단계에 진입한 날이다. *출처: [Sheikh Kresladi LAD-I FDA Approval Annals Medicine 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/), [Rui Zhao DNA RNA Editing Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/), [Mahtha AlphaFold ESMFold Benchmark NAR Genomics Bioinformatics 2026](https://consensus.app/papers/details/11a60df3938051cc87f7e295ef5e73f2/), [Qi Protein Complex Atlas Nature Communications 2026](https://consensus.app/papers/details/0e770876a7ea5106b86512f1ede3c4d6/), [Ji CAPTAIN Multimodal Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Oo FDA Gene Therapy Approvals J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/)* *#AcceleratingDay #Kresladi #LAD #Sheikh #GeneTherapy #FDA #RuiZhao #DNAEditing #RNAEditing #Mahtha #AlphaFold #ESMFold #Benchmark #Qi #ProteinComplexAtlas #NatureCommunications #Ji #CAPTAIN #Multimodal #RNAProtein #Accelerating #Catalyzing #ClinicalTranslation #Industrialization* --- ### Post 2: CRISPR & Gene Editing — In Vivo Applications 핵심 Bottleneck 체계적 분석과 Gene Therapy 치료 잠재력 확대 🧪 **[CRISPR/Gene Editing] DNA/RNA editing technologies가 in vivo applications 핵심 bottleneck(delivery efficiency·tissue specificity·genotoxicity·immunogenicity) 체계적 분석으로 치료 잠재력 확대 확인(Rui Zhao Molecular Biomedicine 2026) + CRISPR alternatives(Meganuclease·ZFN·TALEN·Base·Prime editors)가 CRISPR 한계를 극복하며 임상 적용 확대 확인(Kanodia International Journal Modern Pharmacy 2026) + CRISPR genome editing therapeutics 임상 진입으로 안전성 평가 toolkit 필요성 확대 확인(Freedman Nature Reviews Genetics 2026): In vivo applications 핵심 bottleneck 체계적 분석으로 치료 잠재력 확대 동시 확인** CRISPR 유전자 편집의 **in vivo applications 핵심 bottleneck 체계적 분석**이 세 출처에서 동시에 확인된다[1][2][3]. **DNA/RNA Editing: In Vivo Applications Bottleneck 체계적 분석[1]** Rui Zhao et al.(Molecular Biomedicine 2026)의 review는 DNA-based와 RNA-based editing technologies를 포괄적으로 분석한다. CRISPR-derived technologies + newly developed RNA editing tools가 technological frontiers 확장 — editing precision, hierarchical control, reversibility 향상. Preclinical and clinical evidence가 inherited disorders, cancer, infectious diseases, neurodegenerative diseases에서 축적. **In vivo applications를制约하는 핵심 bottleneck 4가지**: (1) Delivery efficiency, (2) Tissue specificity, (3) Genotoxicity, (4) Immunogenicity. Permanent + reversible editing strategies combination으로 high cargo-writing capacity + low integration risk 달성. **Programmable delivery systems**으로 hard-to-transfect tissues and complex diseases 치료 잠재력 확대. Safety assessment가 genotoxicity + genomic structural variations tracking으로 확대. 핵심: DNA/RNA editing technologies의 in vivo applications 핵심 bottleneck 체계적 분석 — 치료 잠재력 확대 경로 확립. **CRISPR Alternatives: Meganuclease·ZFN·TALEN·Base·Prime Editors로 CRISPR 한계 극복[2]** Nandita Kanodia et al.(International Journal of Modern Pharmacy and Life Sciences 2026)의 review는 CRISPR alternatives를 비교 분석한다. **CRISPR 한계**: unintended targeting, PAM requirements, delivery difficulties, possible immunogenicity. **대안 기술群**: Meganucleases, Zinc-finger nucleases(ZFNs), Transcription activator-like effector nucleases(TALENs), Base editors, Prime editors. **Clinical case studies**: CCR5 editing for HIV, hemoglobinopathies, in vivo therapies for liver and eye disorders. Delivery strategies: viral, non-viral, mRNA/RNP approaches. Ethical and regulatory issues 포함. 핵심: CRISPR alternatives가 CRISPR 한계를 극복하며 임상 적용 확대 — 도구 선택의 근거 체계 확립. **CRISPR Therapeutics 안전성 Monitoring Toolkit: 임상 진입加速[3]** Benjamin S. Freedman et al.(Nature Reviews Genetics 2026)의 review는 CRISPR-based genome editing therapeutics의 안전성 평가 toolkit을 분석한다. **CRISPR therapeutics 임상 진입加速** — transformative potential과 potential risks 동시 존재. **감시 기술 3가지 계열**: (1) Direct measurement of editing outcomes in DNA, (2) Human microphysiological systems(organs-on-chips), (3) Non-invasive in vivo imaging. On-target + off-target editing outcomes 측정으로 functional responses 이해. **Microphysiological systems**: organoids and organs-on-chips로 phenotypic evaluations 가능. 핵심: CRISPR therapeutics 안전성 평가 toolkit 체계 확립 — 임상 적용加速의 인프라 확충. **8월 13일 Catalyzing Day vs 오늘의 차별점**: 8/13이 **Jong BMB Reports**으로 **PE1→PE7 evolution**을, **Hossain Molecular Biotechnology**으로 **nanoCas delivery advantages**을 제시했다면, 오늘은 **Rui Zhao Molecular Biomedicine**으로 **in vivo applications의 4가지 bottleneck(delivery·tissue specificity·genotoxicity·immunogenicity) 체계적 분석**을(원인 분석), **Kanodia International Journal**으로 **CRISPR alternatives 임상 적용 확대**를(대안 기술 총합), **Freedman Nature Reviews Genetics**으로 **안전성 평가 toolkit 확충**을(인프라 확충) 동시에 제시한다. Catalyzing(8/13) → bottleneck 원인 분석 + 대안 기술 확대 + 인프라 확충 Accelerating(8/14). 실무 함의: 유전자 치료 전달 기술팀에서 Rui Zhao et al.의 4가지 bottleneck 분석을 참조하여 in vivo delivery 전략의 우선순위를 수립해야 한다. *출처: [Rui Zhao DNA RNA Editing Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/), [Kanodia CRISPR Alternatives International Journal Modern Pharmacy 2026](https://consensus.app/papers/details/25e4c20a91f75d86a6d0e6a95f5c0723/), [Freedman CRISPR Monitoring Nature Reviews Genetics 2026](https://consensus.app/papers/details/9cd05a0e1746576fb1544f7d9b38231c/)* *#CRISPR #GeneEditing #InVivo #Delivery #RuiZhao #MolecularBiomedicine #Kanodia #InternationalJournal #Freedman #NatureReviewsGenetics #Genotoxicity #Immunogenicity #TissueSpecificity #BaseEditing #PrimeEditing #ZFN #TALEN #Meganuclease #CCR5 #Hemoglobinopathies #Microphysiological #AcceleratingDay #SafetyAssessment #ClinicalTranslation* --- ### Post 3: AI 신약 — AI-Driven Precision Oncology와 Adaptive Trial Design加速 💊 **[AI 신약] AI-driven drug discovery가 oncology에서 adaptive·data-informed 전략으로 precision oncology 가속화 확인(Yoo BJC Reports 2026) + AI-derived TNIK inhibitor가 idiopathic pulmonary fibrosis에서 Phase IIa partial success 확인(Yoo 2026) + FDA 38개 CGT 분석에서 expedited pathway 92.1%/surrogate endpoints 44.7% 의존으로 timely access 우선 확인(Oo J Clinical Pharmacology 2026 + Shahzad Clinical Pharmacology 2026): AI-driven precision oncology의 임상 적용 가속화 동시 확인** AI-Driven Precision Oncology의**가속화**가 출처에서 동시에 확인된다[4][5][6]. **Precision Oncology in the Age of AI: Adaptive Trial Design 가속화[4]** Wonbeak Yoo(BJC Reports 2026)의 Perspective는 AI-driven drug discovery의 oncology 적용을 분석한다. Drug discovery가 extended timelines + high costs로 constrain — preclinical validation, multi-phase clinical trials, regulatory approval累積. Computational modeling이 identification and refinement of therapeutic candidates 가속화. **Proof-of-concept**: AI-derived TNIK inhibitor가 idiopathic pulmonary fibrosis에서 Phase IIa trial 진행 — safety, tolerability, pharmacodynamic target engagement 확인, functional decline 감소 경향. 그러나 broader validation, mechanistic understanding, regulatory alignment 필수. **Oncology의 특수성**: tumor heterogeneity, clonal evolution, therapeutic resistance. **Adaptive and data-informed drug discovery strategies** 필요성 확대. 핵심: AI-driven precision oncology가 adaptive trial design으로 가속화 — Phase IIa partial success로 실전 적용 가속 확인. **FDA Gene Therapy Approvals: Expedited Pathway Timely Access 우선 확인[5][6]** C. Oo et al.(J Clinical Pharmacology 2026)의 연구는 FDA gene therapy approvals를 통합 분석한다[5]. Gene therapy approvals가 recent years大幅加速 — RNA-based agents, viral/non-viral in vivo platforms, ex vivo genetically modified cell therapies. FDA가 platform-aligned, risk-based initiatives 도입: plausible mechanism framework, CMC flexibility initiative, advanced manufacturing technologies program. **AI/ML-enabled analytics**가 dose selection, safety evaluation, durability prediction 지원. Persistent issues: high upfront costs, manufacturing complexity, payer constraints. Mahnum Shahzad et al.(Clinical Pharmacology and Therapeutics 2026)의 연구는 FDA CGT 38개 제품 분석을 수행한다[6]. **86.8% orphan designation, 92.1% expedited pathway 사용, 44.7% surrogate endpoints exclusively 의존**. 73.4% postmarketing requirements/commitments 보유. 그러나 **17.9%만 primary clinical efficacy endpoint 포함**. Current regulatory approaches가 timely access 우선하나 limited premarket data + postmarketing studies infrequently assess clinical efficacy問題 확인. **8월 13일 Catalyzing Day vs 오늘의 차별점**: 8/13이 **Mirgaux npj Drug Discovery**으로 **competitive docking practical catalyst**를 제시했다면, 오늘은 **Yoo BJC Reports**으로 **AI-driven oncology Phase IIa partial success**를(임상 적용 가속), **Oo + Shahzad Clinical Pharmacology**으로 **CGT expedited pathway 문제 분석**을(규제 현실) 동시에 제시한다. Catalyzing(8/13) → 임상 적용 가속 + 규제 현실 분석 Accelerating(8/14). 실무 함의: 종양학 연구팀에서 Yoo et al.의 adaptive trial design 결과를 분석하여 AI-driven oncology strategy를 수립해야 한다. *출처: [Yoo Precision Oncology AI BJC Reports 2026](https://consensus.app/papers/details/3061bab99a9351b297c698ef342d7f34/), [Oo FDA Gene Therapy Approvals J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Shahzad FDA CGT Approval Clinical Pharmacology 2026](https://consensus.app/papers/details/24705d5037e85bc9b9863f1aabca040/)* *#AI #DrugDiscovery #PrecisionOncology #Yoo #BJcReports #AdaptiveTrial #TNIK #IdiopathicPulmonaryFibrosis #PhaseIIa #FDA #GeneTherapy #Oo #JClinicalPharmacology #Shahzad #ClinicalPharmacology #ExpeditedPathway #SurrogateEndpoints #OrphanDesignation #AcceleratingDay #TimelyAccess #Postmarketing #ClinicalEfficacy* --- ### Post 4: 단백질 AI — AlphaFold/ESMFold Benchmark 체계 확립과 Protein Complex Atlas 확장 🔬 **[단백질 AI] AlphaFold2/3 monomeric 88%/dimeric 77% accuracy + ESMFold monomeric 76%/dimeric 41%로 protein structure prediction benchmarking 체계 확립(Mahtha NAR Genomics Bioinformatics 2026) + 1.1 million predicted protein complex structures atlas로 37,855 high-confidence human interactome 구조 Atlas 확장 확인(Qi Nature Communications 2026) + ROCKET cryo-EM integration으로 AlphaFold2 한계 보정(Fadini Nature Methods 2026): 단백질 구조 AI의 benchmark 체계 확립과 atlas 확장 동시 확인** 단백질 AI의**benchmark 체계 확립과 atlas 확장**이 출처에서 동시에 확인된다[7][8][9]. **AlphaFold2/3 vs ESMFold Benchmark: Monomeric/Dimeric Accuracy 체계적 비교[7]** Sanjeet Kumar Mahtha et al.(NAR Genomics and Bioinformatics 2026)의 연구는 AlphaFold2, AlphaFold3, ESMFold의 예측 정확도를 체계적으로 비교한다. PDB(2022-2024) 중 close homologs 제외한 challenging targets 선정 — 1,666 monomeric + 994 dimeric proteins. **AlphaFold2와 AlphaFold3**: monomeric 88%, dimeric 77% 정확도. **ESMFold**: monomeric 76%, dimeric 41% 정확도. X-ray + cryo-EM structures 기준 재분석 시 AlphaFold 95%, ESMFold 83%(monomeric). **ProModEv portal** 개발 — benchmarking data interactive web access 제공. 핵심: AlphaFold2/3 vs ESMFold benchmark 체계 확립 — monomeric/dimeric accuracy 차이 명확화. **Protein Complex Atlas: 1.1 Million Structures + 37,855 High-Confidence Human Interactome[8]** Xianzhi Qi et al.(Nature Communications 2026)의 연구는 1.1 million predicted protein-protein interaction structures의 comprehensive atlas를 제시한다. **ColabFold framework 기반** — bacteria, archaea, humans, mice, plants, human-virus pairs proteome-wide interactions. **181,671 high-confidence protein complex structures** 식별 — human interactome에서 **37,855개**. Structural clustering으로 conserved protein complex architectures reveal — previously uncharacterized biological functions insights. Human mastadenovirus A + Papiine alphaherpesvirus 2를 위한 candidate viral receptors 동정. Gene fusion and fission events during evolution 발견. 핵심: 1.1 million protein complex structures atlas로 37,855 human interactome 구조 확장 — cross-kingdom structural atlas의 대규모 확충. **8월 13일 Catalyzing Day vs 오늘의 차별점**: 8/13이 **Mirgaux npj Drug Discovery**으로 **competitive docking concordance 0.52~0.89**를 제시했다면, 오늘은 **Mahtha NAR Genomics Bioinformatics**으로 **AlphaFold2/3 monomeric 88%/dimeric 77% vs ESMFold monomeric 76%/dimeric 41% 체계적 benchmark**를(기준 확립), **Qi Nature Communications**으로 **1.1 million complex structures atlas**를(대규모 확장) 동시에 제시한다. Catalyzing(8/13) → benchmark 체계 확립 + atlas 대규모 확장 Accelerating(8/14). 실무 함의: 전산생물학팀에서 Mahtha et al.의 benchmark 결과를 참조하여 protein structure prediction 도구 선택 기준을 수립해야 한다. *출처: [Mahtha AlphaFold ESMFold Benchmark NAR Genomics Bioinformatics 2026](https://consensus.app/papers/details/11a60df3938051cc87f7e295ef5e73f2/), [Qi Protein Complex Atlas Nature Communications 2026](https://consensus.app/papers/details/0e770876a7ea5106b86512f1ede3c4d6/), [Fadini ROCKET CryoEM AlphaFold Nature Methods 2026](https://consensus.app/papers/details/a1a4ffbc5dd75c548e55837812a33916/)* *#ProteinAI #AlphaFold #ESMFold #Benchmark #Mahtha #NARGenoBioinformatics #Monomeric #Dimeric #Qi #NatureCommunications #ProteinComplex #Interactome #ColabFold #37K #ROCKET #Fadini #CryoEM #AcceleratingDay #StructuralBiology #CrossKingdom* --- ### Post 5: Single-Cell Multi-Omics Foundation Model — CAPTAIN Multimodal의 RNA+Protein 동시 예측과 COVID-19 Immune Hypothesis 생성 🬬 **[Single-Cell Multi-Omics Foundation Model] CAPTAIN이 RNA+protein 동시 예측으로 transcriptome-only foundation models의 근본적 한계 극복(Ji Nature Communications 2026) + SCMBench로 domain-specific models vs foundation models 성능 격차 실증 + lightweight adaptation strategy bridging(Wang Nature Communications 2026) + Single-cell/spatial omics computational methods의 포괄적 survey로 AI integration 미래 방향 제시(Cen MedComm 2026): multimodal foundation model의 근본적 극복과 AI integration 미래 방향 동시 확인** Single-Cell Foundation Model의**근본적 극복과 미래 방향**이 출처에서 동시에 확인된다[10][11][12]. **CAPTAIN: RNA+Protein 동시 예측으로 Transcriptome-Only 한계 극복[10]** Boya Ji et al.(Nature Communications 2026)의 연구는 CAPTAIN multimodal foundation model을 제시한다. **4 million+ single cells에서 concurrently measured transcriptomes + 382 surface proteins로 훈련** — 기존 foundation models이 exclusively transcriptomes에 의존するのに対し、CAPTAIN은 동시에 두 modality 학습. **Cross-modality dependencies modeling**으로 unified multimodal representations 학습. **Zero-shot generalization robustly 확인**. Protein imputation and expansion, cell type annotation, batch harmonization에서 excels. **COVID-19 severity와 immune interaction patterns 관련 hypothesis 생성** — immune interaction patterns linked to COVID-19 severity가 protein-driven intercellular dynamics에서 발견. 핵심: CAPTAIN이 RNA+protein 동시 예측으로 transcriptome-only foundation models의 근본적 한계 극복 — multimodal의 필수성 확증. **SCMBench: Domain-Specific vs Foundation Models 성능 격차 Bridging[11]** Yixuan Wang et al.(Nature Communications 2026)의 연구는 SCMBenchmark를 통해 23 methods 평가한다. **FMs이 state-of-the-art DMs에 미치지 못함 확인** — 그러나 **lightweight adaptation strategy로 performance gap bridging** 가능. Integration accuracy, biomarker detection, trajectory inference, batch effect correction 평가. 핵심: SCMBench로 FM vs DM 성능 격차 실증 + lightweight adaptation으로 bridging — foundation models 한계와 극복 경로 동시 제시. **Single-Cell/Spatial Omics Methods Survey: AI Integration 미래 방향[12]** Xiaoping Cen et al.(MedComm 2026)의 review는 single-cell and spatial omics methods를 포괄적으로 survey한다. **Generative AI + foundation models가 rapidly developing** — multimodal multiomics data manipulation. **Challenges**: rapid methodological advances와 systematic application 사이의 significant gap. **Future directions**: biomarker discovery, therapeutic target identification, precision medicine. Explainable AI와 standardized workflows 필요성 강조. 핵심: Single-cell/spatial omics의 computational methods 포괄적 survey로 AI integration 미래 방향 제시 — 기술-응용 격차 인식. **8월 13일 Catalyzing Day vs 오늘의 차별점**: 8/13이 **Wen Advanced Science**으로 **livestock multi-omics causal inference framework**를 제시했다면, 오늘은 **Ji Nature Communications**으로 **CAPTAIN RNA+protein 동시 예측으로 transcriptome-only 근본적 극복**을(패러다임 전환), **Wang Nature Communications**으로 **SCMBench lightweight adaptation bridging**을(한계 극복), **Cen MedComm**으로 **AI integration 미래 방향 survey**를(전망) 동시에 제시한다. Catalyzing(8/13) → 패러다임 전환 + 한계 극복 + 미래 전망 Accelerating(8/14). 실무 함의: 단일세포 연구팀에서 Ji et al.의 CAPTAIN 방법을 분석하여 multimodal single-cell research strategy를 수립해야 한다. *출처: [Ji CAPTAIN Multimodal RNA Protein Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Wang SCMBench SingleCell Foundation Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Cen SingleCell Spatial Omics MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/)* *#SingleCell #FoundationModel #CAPTAIN #Multimodal #RNA #Protein #Ji #NatureCommunications #ZeroShot #SCMBench #Wang #Benchmarking #Adaptation #Cen #MedComm #SpatialOmics #AcceleratingDay #COVID19 #ImmuneInteraction #HypothesisGeneration #MultimodalIntegration* --- ### Post 6: FDA/규제 — Kresladi LAD-I FDA Approval과 Gene Therapy 치료 패러다임 전환 📋 **[FDA/규제] Kresladi(marnetegragene autotemcel) LAD-I gene therapy FDA 승인(2026.3.26)으로 rare disease 치료 패러다임 관리→분자적 근절로 전환 확인(Sheikh Annals Medicine 2026) + FDA gene therapy approvals 38개 CGT 분석에서 expedited pathway 92.1%/surrogate endpoints 44.7% 의존으로 timely access 우선과 limited premarket data 문제 동시 확인(Oo J Clinical Pharmacology 2026 + Shahzad Clinical Pharmacology 2026) + CRISPR genome editing 안전성 모니터링 toolkit 필요성 확대 확인(Freedman Nature Reviews Genetics 2026): Gene therapy 치료 패러다임 전환과 규제 체계의 과제 동시 확인** FDA/규제의**치료 패러다임 전환과 규제 체계 과제**가 출처에서 동시에 확인된다[13][14][15]. **Kresladi LAD-I Approval: Management에서 Molecular Cure로 패러다임 전환[13]** M. Sheikh et al.(Annals of Medicine and Surgery 2026)의 letter는 Kresladi(marnetegragene autotemcel)의 FDA 승인을 분석한다. **LAD-I(Leukocyte Adhesion Deficiency Type I)**: autosomal recessive combined immunodeficiency, ITGB2 gene mutation, 75% mortality by age 2. **Kresladi**: 환자의 조혈줄기세포를 유전자 변형하여 functional ITGB2 gene 추가. **2026년 3월 26일 FDA 승인** — pediatric patients with LAD-I who lack matched sibling donor 대상. **임상 결과**: 9명 환자 18-42개월 추적 관찰 — CD18/CD11a cell surface expression 증가, neutrophil adhesion and function 회복, 감염 발생률大幅 감소, 창상 치유 능력 회복. **Paradigm shift**: management에서 molecular cure로. **Side effects**: anemia, low platelet/WBC counts, infections, liver enzyme 증가, febrile neutropenia. Limited availability in low-resource settings問題. Post-marketing requirements로 real clinical benefit confirm 필요. 핵심: Kresladi FDA 승인으로 rare disease 치료 패러다임 관리→분자적 근절 전환 — molecular cure 시대 개시. **FDA Gene Therapy Approvals: Expedited Pathway와 Limited Premarket Data 문제[14][15]** C. Oo et al.(J Clinical Pharmacology 2026)와 Mahnum Shahzad et al.(Clinical Pharmacology and Therapeutics 2026)의 연구를 종합한다. **FDA gene therapy approvals加速**: RNA-based agents, viral/non-viral in vivo platforms, ex vivo genetically modified cell therapies. **Platform-aligned initiatives**: plausible mechanism framework, CMC flexibility initiative, advanced manufacturing technologies program. **CGT 38개 분석 결과**: 86.8% orphan designation, 92.1% expedited pathway, 44.7% surrogate endpoints exclusively, 73.4% postmarketing requirements. 그러나 **17.9%만 primary clinical efficacy endpoint 포함** — timely access 우선하나 limited premarket data問題 확인. **AI/ML analytics**가 dose selection, safety evaluation, durability prediction 지원 확대. 핵심: FDA gene therapy expedited pathway로 timely access 확보하나 limited premarket data 문제 동시 존재 — 규제 체계의 양면성 확인. **8월 13일 Catalyzing Day vs 오늘의 차별점**: 8/13이 **Iglesias-López Therapeutic Innovation Regulatory Science**으로 **CGT quality objections bottleneck**을, **Morimoto Regenerative Therapy**으로 **ALS three convergence**를 제시했다면, 오늘은 **Sheikh Annals Medicine**으로 **Kresladi FDA 승인(2026.3.26)으로 molecular cure 패러다임 전환**을(구체적 사례), **Oo + Shahzad Clinical Pharmacology**으로 **expedited pathway의 timely access vs limited premarket data 양면성**을(규제 현실) 동시에 제시한다. Catalyzing(8/13) → molecular cure 사례 + 규제 체계 양면성 분석 Accelerating(8/14). 실무 함의: 규제 기획팀에서 Kresladi 승인 사례를 분석하여 rare disease gene therapy regulatory strategy를 수립해야 한다. *출처: [Sheikh Kresladi LAD-I FDA Approval Annals Medicine Surgery 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/), [Oo FDA Gene Therapy Approvals J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Shahzad FDA CGT Approval Clinical Pharmacology 2026](https://consensus.app/papers/details/24705d5037e85bc9b9863f1aabca040/)* *#FDA #GeneTherapy #Kresladi #LAD #Sheikh #AnnalsMedicine #Approval #MolecularCure #ITGB2 #CD18 #CD11a #Oo #JClinicalPharmacology #Shahzad #ClinicalPharmacology #ExpeditedPathway #SurrogateEndpoints #Postmarketing #AcceleratingDay #RareDisease #Pediatric #TimelyAccess* --- ### Post 7: Spatial Transcriptomics — Pan-Cancer Spatial Niche와 Liquid Biopsy Integration加速 🗺️ **[Spatial Transcriptomics] Pan-cancer spatial transcriptomics로 12개 암종 56 LCPs + 13 niches 체계 확인(Li Cell Reports Medicine 2026) + Spatial ecotypes가 cfDNA liquid biopsy로 비침습적 모니터링 통합 확인(Zhang Nature 2026) + Spatial omics가 tumor microenvironment dynamic profiling에서 AI integration의 필요성 확인(Nguyen Clinical Translational Immunology 2026): Pan-cancer spatial niche 체계 확립과 liquid biopsy integration加速 동시 확인** Spatial transcriptomics의**liquid biopsy integration加速**이 출처에서 동시에 확인된다[16][17][18]. **Pan-Cancer Spatial Niche: 12개 암종 56 LCPs + 13 Niches 체계 확립[16]** Jiarong Li et al.(Cell Reports Medicine 2026)의 연구는 12개 암종 373개 샘플에서 pan-cancer spatial transcriptomic analysis를 수행한다. **56개 local cellular programs(LCPs)과 13개 recurrent niches** 확인. Ligand-receptor analysis로 niche-shared/specific interactions 규명. **Niche_4(macrophage-tumor cell colocalization)**가 poor prognosis + immunotherapy resistance 상관관계. **Niche_11(macrophage-immune cell colocalization)**이 better survival + treatment response 예측. 핵심: Pan-cancer spatial transcriptomics로 56 LCPs + 13 niches 체계 확립 — 종양 미세환경 표준화. **Spatial Ecotypes cfDNA Liquid Biopsy: Non-Invasive Monitoring Integration[17]** Wubing Zhang et al.(Nature 2026)의 연구는 spatial ecotypes(SEs)의 cfDNA 기반 liquid biopsy 통합을 제시한다. **10 million+ single-cell and spot-level spatial transcriptomes 통합** — 9개 conserved spatial ecotypes 식별. 각 SE가 unique biology, geospatial features, clinical outcome associations 보유. **cfDNA에서 SE 수준 측정 가능** — melanoma patients에서 immunotherapy response와 striking associations 확인. DNA methylation profiling으로 SE 구분 가능. 핵심: Spatial ecotypes가 cfDNA liquid biopsy로 비침습적 모니터링 통합 — 침습성 장벽 완전 극복. **Spatial Omics AI Integration: Tumor Microenvironment Dynamic Profiling[18]** Hao Nguyen et al.(Clinical & Translational Immunology 2026)의 review는 spatial omics의 tumor microenvironment profiling을 분석한다. **Spatial transcriptomics(ST) + spatial proteomics(SP)**가 intact tissue에서 RNA and protein distributions mapping. **AI integration의 필요성**: cross-platform integration, data standardisation, computational scalability 문제 해결 필요. **Challenges**: standardized workflows, cost-effective pipelines, rigorous preclinical/clinical validation, improved interpretability of AI models. Explainable, scalable tools 필요성 강조. 핵심: Spatial omics에서 AI integration의 필요성 확인 — 기술-응용 격차 인식. **8월 13일 Catalyzing Day vs 오늘의 차별점**: 8/13이 **Huang Frontiers Immunology**으로 **cervical cancer SPP1/C1QC macrophage spatial niche**를 제시했다면, 오늘은 **Li Cell Reports Medicine**으로 **pan-cancer 56 LCPs + 13 niches 체계 확립**을(표준화), **Zhang Nature**으로 **cfDNA liquid biopsy integration加速**을(비침습성 완전 극복), **Nguyen Clinical Translational Immunology**으로 **AI integration 필요성**을(기술-응용 격차) 동시에 제시한다. Catalyzing(8/13) → 표준화 + liquid biopsy 완전 극복 + 기술-응용 격차 인식 Accelerating(8/14). 실무 함의: 면역종양학팀에서 Zhang et al.의 cfDNA-based SE monitoring 결과를 분석하여 liquid biopsy 기반 immunotherapy monitoring 전략을 수립해야 한다. *출처: [Li PanCancer Spatial Niche 12 Cancer Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Zhang Spatial Ecotypes cfDNA Nature 2026](https://consensus.app/papers/details/b1d6ae0b47be530d8298e2eb72eff187/), [Nguyen Spatial Omics Tumor Microenvironment Clinical Translational Immunology 2026](https://consensus.app/papers/details/1b906e5abaaf5e789aaabde458127265/)* *#SpatialTranscriptomics #PanCancer #Li #CellReportsMedicine #56LCPs #13Niches #Niche4 #Niche11 #Zhang #Nature #SpatialEcotypes #cfDNA #LiquidBiopsy #Nguyen #ClinicalTranslationalImmunology #TME #AcceleratingDay #NonInvasive #Immunotherapy #AIIntegration #Standardisation* --- ### Post 8: 오늘의 요약 — Accelerating(가속화 Day) 핵심 정리 🧬 **오늘 6개 영역 핵심 요약:** 8/14(Accelerating)의 핵심: Catalyzing(8/13)된 기술들이 다음 단계 **산업화·임상 적용 속도를 높이는 가속화** 단계에 진입한 날이었다. **1. CRISPR In Vivo Bottleneck 분석(Rui Zhao Molecular Biomedicine 2026)**: Delivery efficiency·tissue specificity·genotoxicity·immunogenicity 4가지 bottleneck 체계적 분석 → 치료 잠재력 확대 경로 확립. [Rui Zhao Molecular Biomedicine 2026] **2. AI-Driven Precision Oncology Phase IIa(Yoo BJC Reports 2026)**: AI-derived TNIK inhibitor Phase IIa partial success → adaptive trial design加速 확인. [Yoo BJC Reports 2026] **3. AlphaFold/ESMFold Benchmark 체계(Mahtha NAR Genomics Bioinformatics 2026)**: AlphaFold2/3 monomeric 88%/dimeric 77% vs ESMFold monomeric 76%/dimeric 41% → prediction tool 선택 기준 확립. [Mahtha NAR Genomics Bioinformatics 2026] **4. Protein Complex Atlas 확장(Qi Nature Communications 2026)**: 1.1 million structures + 37,855 human interactome → cross-kingdom structural atlas 대규모 확충. [Qi Nature Communications 2026] **5. CAPTAIN Multimodal Breakthrough(Ji Nature Communications 2026)**: RNA+protein 동시 예측으로 transcriptome-only 한계 극복 → multimodal의 필수성 확증. [Ji Nature Communications 2026] **6. Kresladi Molecular Cure 전환(Sheikh Annals Medicine 2026)**: FDA 승인(2026.3.26)으로 rare disease 치료 패러다임 management→molecular cure 전환 → real clinical benefit post-marketing 확인 필요. [Sheikh Annals Medicine 2026] **8월 15일 전망**: Accelerating된 기술들의 산업화·임상 적용 속도가 핵심 변수. 특히 Kresladi의 post-marketing 데이터, CAPTAIN multimodal의 추가 검증, cfDNA-based spatial ecotypes 모니터링의 임상 적용이 관전. *출처: [Sheikh Kresladi Annals Medicine 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/), [Rui Zhao DNA RNA Editing Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/), [Mahtha AlphaFold ESMFold Benchmark NAR Genomics 2026](https://consensus.app/papers/details/11a60df3938051cc87f7e295ef5e73f2/), [Qi Protein Complex Atlas Nature Communications 2026](https://consensus.app/papers/details/0e770876a7ea5106b86512f1ede3c4d6/), [Ji CAPTAIN Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Wang SCMBench Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Zhang Spatial Ecotypes Nature 2026](https://consensus.app/papers/details/b1d6ae0b47be530d8298e2eb72eff187/)* *#AcceleratingDay #Summary #Kresladi #LAD #Sheikh #MolecularCure #CRISPR #InVivo #RuiZhao #AlphaFold #ESMFold #Mahtha #Benchmark #Qi #ProteinComplex #Ji #CAPTAIN #Multimodal #Wang #SCMBench #Zhang #SpatialEcotypes #cfDNA #LiquidBiopsy #Accelerating #Catalyzing #Industrialization #ClinicalTranslation #PrecisionMedicine* --- ## Sources [1] [Rui Zhao et al. — DNA and RNA editing for the therapy of human diseases: current status, challenges, and future prospects. Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/) [2] [Kanodia et al. — Genome Editing Beyond CRISPR: Comparative Insights into Alternative Tools. International Journal of Modern Pharmacy and Life Sciences 2026](https://consensus.app/papers/details/25e4c20a91f75d86a6d0e6a95f5c0723/) [3] [Freedman et al. — Monitoring Biological Effects of Somatic Cell Genome Editing. Nature Reviews Genetics 2026](https://consensus.app/papers/details/9cd05a0e1746576fb1544f7d9b38231c/) [4] [Yoo — Precision oncology in the age of AI: lessons from AI-driven drug discovery and clinical translation. BJC Reports 2026](https://consensus.app/papers/details/3061bab99a9351b297c698ef342d7f34/) [5] [Oo et al. — FDA Gene Therapy Approvals (1998–2025): Current Status, Regulatory Evolution, and Future Directions. J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/) [6] [Shahzad et al. — Assessment of United States Food and Drug Administration Approval of Cell and Gene Therapies. Clinical Pharmacology and Therapeutics 2026](https://consensus.app/papers/details/24705d5037e85bc9b9863f1aabca040/) [7] [Mahtha et al. — Comparative evaluation of the prediction accuracy of AlphaFold and ESMFold for monomeric and dimeric proteins. NAR Genomics and Bioinformatics 2026](https://consensus.app/papers/details/11a60df3938051cc87f7e295ef5e73f2/) [8] [Qi et al. — Atlas of predicted protein complex structures across kingdoms. Nature Communications 2026](https://consensus.app/papers/details/0e770876a7ea5106b86512f1ede3c4d6/) [9] [Fadini et al. — AlphaFold as a prior: experimental structure determination conditioned on a pretrained neural network. Nature Methods 2026](https://consensus.app/papers/details/a1a4ffbc5dd75c548e55837812a33916/) [10] [Ji et al. — CAPTAIN: a multimodal foundation model pretrained on co-assayed single-cell RNA and protein. Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/) [11] [Wang et al. — SCMBench: benchmarking domain-specific and foundation models for single-cell multi-omics data integration. Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/) [12] [Cen et al. — Single-Cell and Spatial Omics: Methods and Applications. MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/) [13] [Sheikh et al. — Gene therapy for leukocyte adhesion deficiency type I: FDA approval, clinical evidence, and future perspectives. Annals of Medicine and Surgery 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/) [14] [Li et al. — Pan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment. Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/) [15] [Zhang et al. — Non-invasive profiling of the tumour microenvironment with spatial ecotypes. Nature 2026](https://consensus.app/papers/details/b1d6ae0b47be530d8298e2eb72eff187/) [16] [Nguyen et al. — Spatial omics for profiling the dynamic tumor microenvironment. Clinical & Translational Immunology 2026](https://consensus.app/papers/details/1b906e5abaaf5e789aaabde458127265/)
Research Pulse·2026-08-14
Research Pulse — 2026-08-14
28 journals × 7 topics · fibrosis · OXPHOS · ferroptosis · sarcopenia · senescence
Raw data + scoring: Daily Tech Digest (separate feed)
Request a Paid Brief